Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Fc gamma RIIA / CD32a (H167), Avi Tag (Avitag™), 25µg  

Recombinant Biotinylated Human Fc gamma RIIA / CD32a (H167), Avi Tag (Avitag™), 25µg

Biotinylated Human Fc gamma RIIA / CD32a (H167) Protein, Avitag™,His Tag (SPR & BLI verified)

Synonym
recombinant, biotinylated, protein CD32a,FCGR2A,CD32,FCG2 ,FCGR2A1,IGFR2

More details

CDA-H82E6-25

Availability: within 7 days

420,00 €

Background
Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized. There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors.

Recombinant Biotinylated Human FcGR2A / CD32a (H131) Protein was produced using proprietary single-point enzymatic biotinlabeling technology at C-terminus to retain its native conformational structure and, therefore, bioactivity, and has been used successfully for high sensitivity and low variability assays, such as ELISA, western blotting, inhibition assay, pull-down, SPR, FACS, and affinity purification, together with anti-biotin antibody, streptavidin or avidin-conjugated probes.

Source
Biotinylated Human CD32a (H167), Avitag,His Tag (SPR & BLI verified) (CDA-H82E6) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).
Predicted N-terminus: Ala 36

Molecular Characterization
This protein carries an Avi tag (Avitag™)at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 24 kDa. The protein migrates as 30-38 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution
Reconstitute at 100 μg/mL in sterile deionized water. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8° C for 12 months in lyophilized state;
-70° C for 3 months under sterile conditions
after reconstitution.

Bioactivity
Measured by its binding ability in a functional ELISA against immobilized Yervoy Ipilimumab (0.5 µg/well). The linear range is 0.8-25 ng/mL.The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Human FcGR2A / CD32a (H167), His Tag (Cat# CDA-H82E6) can bind Ipilimumab with affinity constant of around 2.3 uM (routinely tested).

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. 

Product specific literature

 (1) Ravetch JV. et al., 2001, Annu Rev Immunol. 19: 275-83.
 (2) Takai T. 2002, Nature Rev Immunol. 2: 580-92.
 (3) Nagarajan S. et al., 2000, Blood. 3: 1069-77.